{"id":"nas-ifn","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"10-30","effect":"Hematologic abnormalities (leukopenia, thrombocytopenia)"},{"rate":"20-40","effect":"Elevated liver enzymes"},{"rate":"5-15","effect":"Depression/mood changes"},{"rate":"10-20","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL210771","moleculeType":"Small molecule","molecularWeight":"549.70"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nucleos(t)ide analogues (NAs) directly inhibit hepatitis B virus reverse transcriptase, reducing viral replication. Interferon-alpha (IFN-α) is an immunomodulatory cytokine that enhances innate and adaptive immune responses against HBV-infected hepatocytes. The combination approach targets both viral suppression and immune activation for chronic hepatitis B treatment.","oneSentence":"NAs+IFN-α combines nucleos(t)ide analogues with interferon-alpha to suppress hepatitis B virus replication and enhance antiviral immune response.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:41:30.561Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B infection"}]},"trialDetails":[{"nctId":"NCT06357806","phase":"NA","title":"The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2024-05-17","conditions":"Chronic Hepatitis B","enrollment":45},{"nctId":"NCT06926647","phase":"","title":"A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2025-05-01","conditions":"HBV, Chronic Hepatitis b","enrollment":2000},{"nctId":"NCT06457477","phase":"NA","title":"Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients","status":"RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2024-06-15","conditions":"Chronic Hepatitis B","enrollment":50},{"nctId":"NCT06368882","phase":"PHASE4","title":"Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoholic Fatty Liver Disease（OCEAN PROJECT）","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2024-01-01","conditions":"Nonalcoholic Fatty Liver Disease, Chronic Hepatitis b","enrollment":1500},{"nctId":"NCT06323681","phase":"NA","title":"Pegylated Interferon α in Previously Interferon-treated CHB（Leading Study）","status":"RECRUITING","sponsor":"Qing XIe","startDate":"2024-02-04","conditions":"Chronic Hepatitis b","enrollment":2016},{"nctId":"NCT04846491","phase":"PHASE3","title":"A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2019-12-04","conditions":"Chronic Hepatitis B","enrollment":475},{"nctId":"NCT03771677","phase":"NA","title":"To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs.","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-12-01","conditions":"Hepatitis B","enrollment":400},{"nctId":"NCT05792878","phase":"","title":"Study of COVID-19 Infection and Its Clinical Prognosis in Chronic Hepatitis B Patients With Antiviral Therapy","status":"UNKNOWN","sponsor":"Beijing Ditan Hospital","startDate":"2022-09-01","conditions":"Chronic Hepatitis B, COVID-19 Infection","enrollment":600},{"nctId":"NCT04565262","phase":"PHASE4","title":"Study on Antiviral Therapy for HBeAg-positive Chronic Hepatitis B Patients Aged 1-16 Years","status":"UNKNOWN","sponsor":"Beijing 302 Hospital","startDate":"2020-09","conditions":"HBeAg Positive Chronic Hepatitis B","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"NAs+IFN-α","genericName":"NAs+IFN-α","companyName":"Beijing 302 Hospital","companyId":"beijing-302-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NAs+IFN-α combines nucleos(t)ide analogues with interferon-alpha to suppress hepatitis B virus replication and enhance antiviral immune response. Used for Chronic hepatitis B infection.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}